The ATON System uses optical spectroscopy to quantify molecules
Laser light causes the molecules in the sample to vibrate. Sensors collect molecular signatures from scattered light. The software reports the concentrations of each target in the multiplex test panel. Rapid results inform experimental design.
Atonarp will develop and sell less complex, affordable analyzers and reagents for high-multiplex cell-based tests for scientists in pharma/biotech, academia and government. We intend to establish the technology in non-regulated markets first, then continue product development to offer a portfolio of high-value in vitro diagnostic tests.
A comprehensive understanding of fundamental biology, disease pathways, and drug mechanism of action requires the integration of information from a large number of related pathways. Multiplexed measurements are attracting considerable interest in single-cell biology and systems biology. Current methods are expensive and/or difficult to implement.
Atonarp plans to develop optical spectroscopy applications for cell-based assays in basic research and in bioprocessing applications including:
· Immunophenotyping as an alternative to flow cytometry and mass spectrometry
· Cell imaging
· Study cell surface proteins, e.g., multiplex biomarker expression for targeted therapies, immune response.
· Cell count, viability, cytotoxicity assays used to assess effectiveness cell/gene therapies
Count/characterize cell populations and protein expression
Experiments that study cells and target specific components using antibodies
Measure immune response, metabolism, apoptosis, cellular processes, viability
Atonarp plans to develop tests to assess patients with symptoms of heart attack.
• Over 10 million Americans go to the emergency department with chest pain each year. Although only 13% of them have had a heart attack, but 66% are admitted to the hospital.
• Implementing testing with a high sensitivity troponin test can increase discharge rate from 34% to 75%, which could save $7 billion per year.
Troponin leaks from dead heart cells. It is used to diagnose heart attack.
Safely discharge low-risk patients or admit patients with heart attack faster.
Discharging patients quickly eases crowding in the ED and allows efficient care of more patients.
Atonarp plans to develop point-of-care, multiplex tests for inflammatory and sepsis biomarkers in blood.
Inflammatory biomarkers are associated with severe infection and sepsis and can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for “cytokine storm,” which is an out-of-control immune response that is associated with bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response and help inform treatment decisions.
Speed matters. Sepsis can progress rapidly and can be fatal. Each hour of delay in giving antibiotics increases risk of death by 7%.
Costs $27 billion annually in the U.S.
Sepsis affects 30 million people worldwide and causes 6 million deaths annually.
Atonarp is developing our multi-laser optical spectroscopy technology for non-invasive, transdermal measurement of glucose to monitor patients with diabetes.
Non-invasive testing replaces fingersticks
Modify diet, exercise and medications
Better control improves outcomes and reduces costs